Bioanalysis of Today and Tomorrow: Current Best Practices and Emerging Technologies Enabling Diverse Therapeutic Conjugate Evaluation | An ISSX 2024 Virtual Workshop

Bioanalysis of Today and Tomorrow: Current Best Practices and Emerging Technologies Enabling Diverse Therapeutic Conjugate Evaluation | An ISSX 2024 Virtual Workshop

  • Register
    • Non-member - $400
    • Member - $300
    • Student - $150
    • Premier - $300

    Continue

This workshop is organized through the efforts of the ISSX Bioanalysis in ADME Science Focus Group and is organized by Drs. Matthew Albertolle, Bingming Chen, Joe Cannon, Mei Han, Thomas Kraft, John Tran, Jim Shen, Faye Vazvaei, and Brian Booth.

The scope of this workshop is to provide content for attendees from early career/grad school who want to learn fundamentals (Day 1) to senior career leaders in the field who want to learn about what is the new and emerging technologies (Day 2). Workshop topics can include bioanalytical techniques, including biotransformation (and subsequent bioanalysis) of macromolecules. Each session of the workshop consists of presentations from several expert speakers. In addition, there will be an interactive virtual poster session which will be selected from the pool of abstracts from attendees. 

  • Day 1: Bioanalysis of Today
    Contains 6 Component(s)

    This session reviews the bioanalytical basics, including experimental design, how samples are analyzed, and what the data is used for.

    Co-Chairs: Matthew Albertolle and Valerie Kramlinger

    Practical Considerations in Preclinical ADC Bioanalysis

    image Linlin Dong, Takeda Pharmaceuticals, Cambridge, MA, USA

    Bioanalysis of Anti-body Oligonucleotide Conjugates

    image Long Yuan, Biogen, Cambridge, MA, USA

    Regulated Bioanalytical Support for ADC Drug Development

    image Jian Chen, BMS, Summit, NJ, USA

    Physiologically-based Pharmacokinetics Meets Quantitative Protein Mass Spectrometry for Mechanistic Modeling of Target-mediated Drug Disposition (TMDD)

    image Armin Sepp, Certara, Cambridge, United Kingdom

  • Day 2: Bioanalysis of Tomorrow
    Contains 8 Component(s)

    This session focuses on modern techniques that may or may not work with newer modalities

    Co-Chairs: Faye Vazvaei, Mei Han, Joe Cannon, and Jim Shen

    Biotransformation of ADC Linkers and Payloads

    image Donglu Zhang, Genentech, South San Francisco, CA, USA

    Characterizing Antibody Drug Conjugates by Direct Mass Technology

    image Rachel Shi, Genentech, South San Francisco, CA, USA

    Mathematical Modeling for Antibody Drug Conjugates

    image Ankit Shah, US FDA, Silver Spring, MD, USA

    Challenges and Solutions in ADC Bioanalysis: Case Studies of LBA and LC-MC/MS Technologies

    image Cynthia Chavez-Eng, Merck, West Point, PA, USA

    Discovery Bioanalysis for ADC Therapeutics 

    image Yifan Shi, Johnson and Johnson, Spring House, PA, USA